Executive Summary
Oxford BioMedica pls is a leading gene therapy company. It is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University. Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how. Oxford BioMedica is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 85 split between its main facilities in Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.
For the six months ended December 2007, The Company made revenueS of £7.2m and an operating loss of £19.8m.[1]
Company History
- Oxford BioMedica was established in 1995 as a spin out from Oxford University.
- The company listed on AIM in 1996 and moved to the official list of the London Stock Exchange in 2001.
Current Events
Business Model
The Company's commercial strategy is to develop products using its proprietary technologies. For certain therapeutic markets, Oxford BioMedica will seek partners for late-stage development and commercialisation. For selected products, the Company will look to co-develop and co-commercialise with partners, enabling Oxford BioMedica to retain more value from the commercialisation of its products and move towards a fully integrated business model with specialty sales and marketing capabilities.
Oxford BioMedica has created a broad pipeline of development candidates that use genes as the direct or indirect mediators of a therapeutic effect. The Company's advanced development pipeline includes treatments for cancer, Parkinson's disease and retinopathy. The Company's early stage development pipeline includes preclinical candidates for Stargardt disease, motor neuron disease, spinal muscular atrophy and AIDS.
Main Products
The Company's advanced development pipeline is comprised of five gene-based product candidates. The lead product, TroVax®, is a therapeutic cancer vaccine for multiple solid cancers that is being developed and commercialised in collaboration with sanofi-aventis. TroVax is currently in Phase III development for renal cancer (see www.trovax.co.uk...). Phase III trials of TroVax in colorectal cancer are expected to start in 2008 and a Phase II trial in prostate cancer is ongoing. ProSavin® is a gene-based treatment for Parkinson's disease, which is potentially a one-off treatment to produce a new source of dopamine in the striatum of the brain. Oxford BioMedica initiated a Phase…
